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Abstract
Background: Acute retinal necrosis is a rare but devastating ocular condition. We report two cases of acute retinal
necrosis in immunocompetent patients, complicated by cystoid macular oedema and treated with intravitreal
dexamethasone (OZURDEX®) implant.
Results: Two patients diagnosed with acute retinal necrosis were treated with intravenous acyclovir. Both of
them developed cystoid macular oedema following resolution of viral retinitis. Ocular condition of the first patient was
further complicated by central serous chorioretinopathy. Under unavoidable circumstances, cystoid macular oedema in
both the patients was treated with intravitreal dexamethasone implant with great caution. Resolution of
cystoid macular oedema without recurrence of viral retinitis was noted in the long-term follow-up.
Conclusions: Findings of the case report should be interpreted cautiously, and extreme caution should be
exercised prior deciding the management with a corticosteroid implant in patients with viral retinitis. However,
intravitreal dexamethasone implant can be a useful option in selected patients with cystoid macular oedema in acute
retinal necrosis.
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Findings
Introduction
Acute retinal necrosis (ARN) is an uncommon, devastating,
and potentially blinding necrotizing retinitis. It is most
commonly seen in healthy young individuals, but can be
seen in immunocompromised patients also [1]. ARN is a
clinical diagnosis, and polymerase chain reaction of
the vitreous or aqueous aspirate can be used to identify
the viral DNA responsible for the disease [1]. The major
causes of poor visual outcome in a case of ARN are retinal
detachment, optic nerve, or macular involvement by
ischemic vasculopathy [2]. Involvement of the posterior
pole is relatively uncommon, except for inflammatory
macular oedema, epimacular membrane formation, or
retinitis in untreated or late stages of the disease.
Cystoid macular oedema in these patients tends to be
recurrent and resistant to treatment, threatening cen-
tral vision even after resolution of ocular inflammation
and requires additional treatment [3].
We report two cases of ARN in immunocompetent
patients, complicated by cystoid macular oedema and




A 36-year-old, otherwise healthy woman presented to us
with sudden painless reduction of vision in her left eye
since 1 month. She was diagnosed with ARN elsewhere
20 days back and was on oral valacyclovir 1 g twice a
day and oral steroid 20 mg/day.
On examination, her best corrected visual acuity
(BCVA) was 6/6, N6 in the right eye and 6/18, N 36 in
the left eye. Slit lamp and fundus examination was
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essentially normal in the right eye. The left eye
showed 1+ anterior chamber cells and flare. Fundus
examination of the left eye showed moderate vitritis
and resolving necrotizing retinitis (Fig. 1a). Aqueous
aspirate, obtained via anterior chamber paracentesis,
was sent for PCR analysis and found to be positive
for varicella zoster viral genome.
The patient was started on intravenous acyclovir
500 mg three times a day. Subsequently, she was started
on oral corticosteroid 40 mg/day. After 3 weeks of intra-
venous therapy, oral valacyclovir 1 g three times was
started with tapering of oral steroids. Within 3 weeks,
with resolving vitritis and retinitis, her BCVA improved
to 6/7.5, N10. Prophylactic laser treatment was applied
on the normal retina to surround the posterior edge of
the necrotic retina by rows of confluent and circumfer-
ential laser burns (Fig. 1b).
Her condition remained stable for 3 months when she
came back with a drop in vision, and her BCVA in left
eye was 6/9, N10. Fundus examination revealed cystoid
macular oedema (CME) in the left eye, which was
confirmed in optical coherence tomography (OCT)
with thickness of 422 μ. She was started on topical
nepafenac, and dose of oral steroid was hiked up to
50 mg/day.
She came back after a month with sudden drop in vision
in her left eye. Her BCVA in the left eye was 6/36, N12.
Fundus examination of the left eye revealed pocket of
subretinal fluid in the inferotemporal quadrant. Fluorescein
angiography (FFA) confirmed the presence of central
serous chorioretinopathy (CSR) (Fig. 1c). Optical
coherence tomography (OCT) confirmed the presence
of CSR with deterioration of CME in the left eye with
thickness of 573 μ (figure). She was advised to stop
oral steroid, and focal laser to the leak was done. She
came back after a month with resolved CSR and
persistent CME, and her BCVA improved to 6/12, N9
in the left eye.
She came back with significant vitritis with persistent
CME after 2 months. OCT showed deterioration of her
CME with a thickness of 724 μ (Fig. 2a). Her BCVA
dropped to 6/45. Intravitreal sustained-release dexa-
methasone implant (Ozurdex) was injected under
antiviral cover in the left eye. She was kept under close
follow-up and she received another injection after
3 months. Following two injections, her BCVA improved
to 6/9, with marked subjective improvement in overall
visual function (Fig. 2b). No reactivation of the viral
retinitis was observed at the end of 2 years of follow-up.
She received oral antiviral medications for 8 months
following intravitreal implant administration.
Patient 2
A 39-year-old, otherwise healthy man presented with
reduction of vision in the left eye 2 weeks prior to
presentation. On examination, his best corrected visual
acuity (BCVA) was 6/24 in the left eye and 6/6 in the
right. An examination of the anterior segment in the left
eye showed multiple granulomatous pigmented KP and 1
+ anterior chamber cell reaction with minimal flare. Fun-
dus examination of the left eye revealed moderate vitritis,
inflammatory optic disc oedema, peripheral confluent
Fig. 1 Left eye of a 36-year-old lady with acute retinal necrosis. a.
Color fundus pictures at the initial presentation. b. Healed retinitis
with prophylactic laser treatment. c. Fundus Fluorescein
Angiography showing leak in the inferotemporal quadrant
Fig. 2 OCT of the left eye showing. a. Cystoid macular oedema and
b. Resolved cystoid macular oedema after two doses of intravitreal
dexamethasone implant with oral antiviral treatment
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areas of retinal necrosis with hemorrhages, and vasculitis
involving the retinal arterioles (Fig. 3a). An examination
of the right eye was unremarkable. A diagnosis of
ARN was made, and treatment with oral valacyclovir
1 g three times a day was commenced together with
oral steroids 40 mg/day. Topical steroid prednisolone
acetate 1% drop four times a day was started to con-
trol anterior chamber inflammation. The resolution of
the retinitis was noted after 6 weeks with BCVA of 6/
9. Patient was maintained on valacyclovir 500 mg BID
(twice a day) and advised for follow-up.
After 4 months, he returned to the clinic reporting
further decrease of vision in the previously affected eye.
His BCVA in the left eye was 6/36. Fundus examination
revealed some vitreous floaters and a blunted foveal re-
flex. No reactivation of retinitis was noted. SD-OCT re-
vealed the formation of cystoid macular oedema with
retinal thickness measuring 508 μ (Fig. 3b). The patient
was commenced on oral valacyclovir 1 g tid, and advised
for pars plana vitrectomy. After 3 weeks, there was a re-
markable resolution of CME, and BCVA improved to 6/
12. Treatment was tapered to 1 g valacyclovir, and retin-
itis remained quiescent over follow-up.
Two months later, patient returned with a drop in vi-
sion in the left eye. His BCVA was 6/24, N12 and SD-
OCT revealed deterioration of CME with retinal thick-
ness of 465 μ (Fig. 3c). Anti-VEGF injection was given
with no improvement in BCVA or OCT 1 month later.
Since he had declined all systemic forms of therapy, the
patient was counselled to administer an Ozurdex injec-
tion. Valacyclovir was increased to 1 g three times day.
One month after injection, his BCVA improved to 6/9
and retinal thickness reduced to 265 μ with complete
resolution of CME (Fig. 3d). She was continued oral
antiviral for 6 months following intravitreal injection of
Ozurdex.
Three months later, she came back with a drop in
BCVA and fundus examination revealed recurrence of
CME in the left eye. She was treated with a repeat Ozurdex
injection which resulted in resolution of CME with BCVA
of 6/12 in 6 weeks.
Discussion
ARN is a severe necrotizing vasoocclusive retinitis
caused by herpes viruses. In the absence of appropriate
treatment, retinitis progresses circumferentially with
subsequent devastating visual outcome. Posterior pole
involvement with retinitis is uncommon and includes
the development of macular oedema, epimacular mem-
branes, macular holes, and macular ischemia.
Although signs of intraocular inflammation disappear
usually between 6 and 12 weeks following the onset of
treatment, post ARN macular oedema can pose a
chronic recurrent problem and a therapeutic challenge,
with possible consequent reduction of central vision. CSR
in ARN is very rare, but has been reported in literature [4].
The role of systemic corticosteroid therapy in control-
ling intraocular inflammation and resolution of the
vitritis in ARN is generally well accepted [5]. Literature
on use of intravitreal corticosteroid in ARN is sparse. In
fact, local administration of corticosteroid has been
implicated to reactivate viral retinitis [6–8]. However, in
Fig. 3 Left eye of a 39-year-old man with acute retinal necrosis. a: Areas of confluent necrotizing retinitis and occlusive arteritis in a patient of
acute retinal necrosis. b: Epimacular membrane with macular edema presenting 4 months after resolution of acute phase of ARN. c: Cystoid
macular edema causing a later drop of vision to 6/24 six months after quiescence of ocular inflammation. d: Resolution of macular edema
demonstrated in SD-OCT 3 weeks after dexamethasone ocular implant with oral antiviral treatment
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many of the cases reported, there were associated
comorbidities and many of these patients were on
immunosuppression for a long time [6]. Thus, definitive
proof for potential risk of developing necrotizing retinitis
following periocular or intraocular corticosteroids is yet
to be ascertained.
Management of cystoid macular oedema following
viral uveitis is always challenging and frustrating. There
is no standard treatment regimen for uveitic macular
oedema. Various available treatment modalities for uvei-
tic macular oedema include topical, regional and sys-
temic corticosteroids, immunosuppressive, and VEGF
inhibitors. VEGF inhibitors have been tried in uveitic
macular oedema with variable results [9–11]. The role of
intravitreal corticosteroid in cystoid macular oedema has
been well-established. However, the use of intravitreal
steroid in infectious retinitis remains questionable and
should not be advocated as primary treatment modality.
Intravitreal triamcinolone (IVTA) in adjuvant with intra-
vitreal foscarnet has been used to treat optic nerve
oedema in a patient with acute retinal necrosis [12].
Choudhury et al. [13] treated four eyes of ARN with IVTA
under oral antiviral cover in absence of new active lesions.
Our cases illustrate the clinical efficacy of Ozurdex in
the treatment of CME in patients with ARN. However,
extreme caution should be exercised prior deciding the
management with a corticosteroid implant in patients
with viral retinitis. In the absence of active necrotizing
retinitis and long-term treatment with antiviral agents,
Ozurdex can be a useful tool for the management of
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